/IMMB

IMMB Stock - Immunotech Laboratories, Inc.

Q: What is the analyst price target for IMMB?

Analyst price target information is not currently available for IMMB.

Q: What is IMMB's market cap?

Market capitalization information is not currently available for IMMB.

Healthcare|Medical - Pharmaceuticals|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Jan 12

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IMMB

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2004

FY2005

FY2009

FY2013

FY2016

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-77.02

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2016	FY2013	FY2009	FY2005	FY2004
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-305,553	$-547,428	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-470,361	$-603,169	$-958,935	$-2,027,415	$-110,335
Net Income	$-493,029	$-625,837	$-977,570	$-33,595,348	$-111,135
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.00	$-0.00	$0.00	$-802.00	$-43.00

Company Overview

Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Eco-Petroleum Solutions, Inc.

Visit Website

Frequently Asked Questions about IMMB

What is IMMB's current stock price?

Immunotech Laboratories, Inc. (IMMB) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for IMMB?

No analyst price targets are currently available for this stock.

What sector is Immunotech Laboratories, Inc. in?

Immunotech Laboratories, Inc. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the OTC exchange.

What is IMMB's market cap?

Immunotech Laboratories, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does IMMB pay dividends?

No, Immunotech Laboratories, Inc. does not currently pay a dividend to shareholders.